Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fostamatinib and Paclitaxel in Ovarian Cancer
NCT03246074Phase 1Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Apr 2018
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fostamatinib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (3 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Safety and Tolerability of Fostamatinib at 28 days and Maximum Tolerated Dose of Fostamatinib at 28 days. Started Apr 2018; status: completed.
02
Drugs
fostamatinib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03246074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03246074.